EA200900593A1 - Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака - Google Patents

Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака

Info

Publication number
EA200900593A1
EA200900593A1 EA200900593A EA200900593A EA200900593A1 EA 200900593 A1 EA200900593 A1 EA 200900593A1 EA 200900593 A EA200900593 A EA 200900593A EA 200900593 A EA200900593 A EA 200900593A EA 200900593 A1 EA200900593 A1 EA 200900593A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
optionally substituted
ring
polo
inhibitors
Prior art date
Application number
EA200900593A
Other languages
English (en)
Russian (ru)
Inventor
Дэвид Фестус Чарльз Моффат
Санджей Ратилал Пэтел
Стефен Джон Дэвис
Кеннет Уильям Джон Бейкер
Оливер Джеймс Филпс
Original Assignee
Хрома Терапьютикс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0621205A external-priority patent/GB0621205D0/en
Priority claimed from GB0715614A external-priority patent/GB0715614D0/en
Application filed by Хрома Терапьютикс Лтд. filed Critical Хрома Терапьютикс Лтд.
Publication of EA200900593A1 publication Critical patent/EA200900593A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA200900593A 2006-10-25 2007-10-19 Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака EA200900593A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0621205A GB0621205D0 (en) 2006-10-25 2006-10-25 Inhibitors of PLK
GB0715614A GB0715614D0 (en) 2007-08-10 2007-08-10 Inhibitors of plk
PCT/GB2007/003998 WO2008050096A1 (en) 2006-10-25 2007-10-19 Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer

Publications (1)

Publication Number Publication Date
EA200900593A1 true EA200900593A1 (ru) 2010-06-30

Family

ID=38896021

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900593A EA200900593A1 (ru) 2006-10-25 2007-10-19 Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака

Country Status (13)

Country Link
US (1) US20100216802A1 (enExample)
EP (1) EP2079743B1 (enExample)
JP (1) JP2010507639A (enExample)
KR (1) KR20090071668A (enExample)
AT (1) ATE542820T1 (enExample)
AU (1) AU2007310604B2 (enExample)
BR (1) BRPI0718120A2 (enExample)
CA (1) CA2665736A1 (enExample)
EA (1) EA200900593A1 (enExample)
IL (1) IL198082A0 (enExample)
MX (1) MX2009004244A (enExample)
NZ (1) NZ577153A (enExample)
WO (1) WO2008050096A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
JP5043120B2 (ja) * 2006-10-30 2012-10-10 クロマ セラピューティクス リミテッド ヒストンデアセチラーゼの阻害剤としてのヒドロキサメート
ATE497961T1 (de) 2006-12-14 2011-02-15 Vertex Pharma Als proteinkinaseinhibitoren geeignete verbindungen
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
GB0807451D0 (en) * 2008-04-24 2008-05-28 Chroma Therapeutics Ltd Inhibitors of PLK
CA2728830A1 (en) * 2008-06-23 2010-01-21 Jean-Damien Charrier Protein kinase inhibitors
MX346186B (es) 2008-06-23 2017-03-10 Vertex Pharma Inhibidores de proteina cinasas.
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
CN102656151A (zh) * 2009-09-04 2012-09-05 扎里卡斯药品有限公司 治疗疼痛和癫痫的取代的杂环衍生物
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
DK3222616T3 (da) 2012-10-17 2019-08-19 Macrophage Pharma Ltd N-[2-{4-[6-amino-5-(2,4-difluorbenzoyl)-2-oxopyridin-1(2H)-yl]-3,5-difluorphenyl}ethyl]-L-alanin og terbutylester deraf
US10208023B2 (en) 2013-03-01 2019-02-19 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
CA2936871A1 (en) * 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
CN106029653A (zh) 2014-01-31 2016-10-12 达纳-法伯癌症研究所股份有限公司 二氨基嘧啶苯砜衍生物及其用途
HK1256417A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 氰基噻吩並三唑並二氮雜環庚三烯及其用途
RU2742035C2 (ru) 2015-11-25 2021-02-01 Дана-Фарбер Кэнсер Инститьют, Инк. Бивалентные ингибиторы бромодоменов и пути их применения
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
EP3833353A4 (en) * 2018-08-10 2022-08-24 Yale University Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same
CN111039944B (zh) 2018-10-12 2021-11-23 中国科学院合肥物质科学研究院 Mst1激酶抑制剂及其用途
KR102260995B1 (ko) * 2018-11-28 2021-06-04 국립암센터 Plk1의 활성 억제제를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
CN115947728B (zh) * 2021-10-09 2024-01-09 沈阳药科大学 含磺酰基的二氢喋啶酮衍生物及其应用
US20230263783A1 (en) 2022-02-18 2023-08-24 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization
CN118047779B (zh) * 2022-11-09 2025-02-11 沈阳药科大学 含苯联杂芳基的二氢喋啶酮衍生物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP2008510770A (ja) * 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｌｋ阻害剤としての新規プテリジノン
WO2006021548A1 (de) * 2004-08-27 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel

Also Published As

Publication number Publication date
US20100216802A1 (en) 2010-08-26
BRPI0718120A2 (pt) 2013-11-12
CA2665736A1 (en) 2008-05-02
ATE542820T1 (de) 2012-02-15
EP2079743B1 (en) 2012-01-25
AU2007310604B2 (en) 2012-02-02
WO2008050096A1 (en) 2008-05-02
KR20090071668A (ko) 2009-07-01
AU2007310604A1 (en) 2008-05-02
NZ577153A (en) 2012-02-24
EP2079743A1 (en) 2009-07-22
JP2010507639A (ja) 2010-03-11
MX2009004244A (es) 2009-05-14
IL198082A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
EA200900593A1 (ru) Производные птеридина как ингибиторы polo-подобной киназы, применяющиеся при лечении рака
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
ES2509820T3 (es) Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer
ES2524966T3 (es) Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer
MX2012002059A (es) Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa.
BR0316146A (pt) Derivados de amida do ácido 3-(2-hidróxifenil)-1h-pirazol-4-carboxìlico como inibidores de hsp90 para o tratamento de câncer
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
PE20151981A1 (es) Pontenciador de inhibidores del homologo de zeste
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
MY173930A (en) Crystalline solvates and complexes of (is)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
NO20061157L (no) 4-pyramidonderivater og deres anvendelse som peptidylpeptidmeinbibitorer
MX2011007499A (es) Derivados de pirimidin-carboxamida como inhibidores de la cinasa syk.
PE20130149A1 (es) Derivados de la cromenona con actividad anti-tumoral
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
PE20110213A1 (es) Derivados de indolinona como inhibidores de quinasa
PE20090216A1 (es) Compuestos triazolil aminopirimidina
MX2010000658A (es) Derivados de pirimidina 934.
NZ592429A (en) PHENANTHROINDOLIZIDINE DERIVATIVE AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
WO2006123165A3 (en) Pyrimidine derivatives as hsp90 inhibitors
NZ592392A (en) PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
WO2008110690A3 (fr) Nouveaux derives indoliques, leurs procedes de preparation et leurs utilisations notamment en tant qu'antibacteriens